Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2018-04-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2018年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "华兰生物工程股份有限公司 2018 年第一季度报告全文" which translates to "Hualan Biological Engineering Co., Ltd. 2018 First Quarter Report Full Text." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and management commentary on financial performance for the first quarter of 2018. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it is the full report, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2018
2018-04-26 Chinese
2018年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 First Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as revenue, net profit, earnings per share, cash flow, and shareholder information for the first quarter of 2018. The presence of actual financial statements and substantive financial data confirms it is a comprehensive interim report rather than a brief announcement or certification. The document length (6022 characters) supports it being a full report rather than a short notice. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2018-04-26 Chinese
关于举行2017年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding a 2017 annual performance explanation meeting (业绩说明会), specifying the date, time, and platform for the event. It mentions company executives who will attend and invites investors to participate. There is no detailed financial data or report content included, only information about the meeting itself. This fits the definition of an Investor Presentation (IP), as it is a detailed presentation for investors focusing on financials and company performance. The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is Investor Presentation (IP).
2018-04-08 Chinese
关于控股子公司取得A群C群脑膜炎球菌多糖疫苗生产批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (462 characters) regarding the receipt of a production license for a vaccine by a subsidiary of the company. It includes a statement of truthfulness by the board and mentions future information disclosure obligations. There are no financial statements, detailed financial data, or comprehensive reports. The document is an official announcement about a regulatory approval event, not a financial report or detailed management discussion. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories.
2018-03-27 Chinese
2017年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2017 by 华兰生物工程股份有限公司. It discusses the company's internal control evaluation, including financial and non-financial internal control effectiveness, defect classification, and remediation status. The content is detailed and comprehensive, covering governance, risk management, and internal control systems, which aligns with an Audit Report or Internal Control Report rather than a full Annual Report or other categories. It is not a brief announcement or a certification letter but a substantive report on internal controls. Therefore, the document fits best under the Audit Report / Information (AR) category. FY 2017
2018-03-26 Chinese
第六届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the sixth board of directors' ninth meeting of 华兰生物工程股份有限公司. It includes approvals of the 2017 annual general manager work report, board work report, 2017 annual report and summary, 2017 financial final accounts, profit distribution plan, internal control self-evaluation report, social responsibility report, appointment of audit firm, guarantees for subsidiaries, and appointment of senior management. The document also references the 2017 annual report and social responsibility report being published elsewhere (on 巨潮资讯网 and in the Securities Times). The document is 2908 characters long, which is relatively short and mainly summarizes board meeting resolutions rather than containing the full annual report or financial statements. It also includes the appointment of a new senior management member. Given the content focuses on board meeting resolutions and management appointments, and the actual reports are referenced as published elsewhere, this document fits best as a Board/Management Information (MANG) filing rather than the full Annual Report (10-K) or other report types. Therefore, the classification is MANG with high confidence.
2018-03-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.